Dr. Reddy's Laboratories
Search results
6 days ago · Driven by our collective vision of transforming healthcare and transforming patients’ lives, Biocon Biologics is making healthcare affordable and importantly accessible to millions of patients and their families across the world.
Biocon Biologics is today one of the frontrunners in the global biosimilars industry, working to provide patients access to affordable biologics and enable health equity worldwide. Driven by a Purpose to Address Unmet Needs for Affordable Biologics.
6 days ago · Biocon is an innovation led fully integrated biopharmaceutical company that develop affordable biosimilars, generic formulations & complex APIs.
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and...
Products. Over the years, Biocon Biologics has grown into a leading global biosimilars player, enabling affordable access to life-saving medicines and transforming patients’ lives across the world.
Nov 29, 2022 · Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), announced today that it has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of its partner Viatris Inc. (NASDAQ: VTRS).
A global biopharmaceutical company changing patients’ lives by finding new & affordable ways to treat diabetes, cancer & autoimmune diseases.
6 days ago · Biocon Biologics is an international fully integrated biosimilar subsidiary of listed Biocon Limited. Biocon Biologics offers a portfolio of eight commercialised biosimilars across the globe which include Insulin Glargine, Insulin Aspart, recombinant Human Insulin, Trastuzumab, Bevacizumab, Pegfilgrastim, Adalimumab and Etanercept. The company expects to include 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. ...
5 days ago · Biocon Biologics, a global biosimilars company and a subsidiary of Biocon Ltd has received approval from European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab, a type of targeted ...
6 days ago · New Delhi: Biocon on Monday said its unit Biocon Biologics has received approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab at its new facility at Bengaluru.
